Agenda for November 2026 Mental Health Advisory Committee meeting

Information on what the Mental Health Advisory Committee will be considering at its upcoming meeting in November 2026.

Reviewing the access criteria for medicines for attention deficit hyperactivity disorder (ADHD)

The Committee will discuss current special authority criteria for medicines used for ADHD and consider the need for alterations.

Guanfacine (branded as Intuniv) for ADHD

The Committee will discuss an application for guanfacine for people with ADHD.

Guanfacine (branded as Intuniv) for ADHD traits in autism spectrum disorder (ASD)

The Committee will discuss an application for guanfacine for people with Autism Spectrum Disorder (ASD) who experience symptoms of ADHD.

Guanfacine (branded as Intuniv) for ADHD traits in people with Prader-Willi syndrome (PWS)

The Committee will discuss an application for guanfacine for people with Prader-Willi syndrome (PWS) who experience symptoms of ADHD.

Naltrexone hydrochloride (branded as Naltraccord) for alcohol use disorder

The Committee will discuss an application to amend the Special Authority criteria for naltrexone hydrochloride for people with alcohol dependence. This application seeks to widen access by amending the special authority criteria to include primary healthcare providers.

Clozapine intramuscular (branded as Clozapine) for treatment refractory psychotic disorder

The Committee will discuss an application for intramuscular clozapine for people with treatment resistant psychotic disorders.